World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
117
Citations
47090
World Ranking
4225
National Ranking
126

Piero Picci publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Piero Picci sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 654 publications — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Piero Picci D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Piero Picci sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 117 D-Index — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Piero Picci is affiliated with the University of Bologna in Italy and has a primary focus in the field of medicine, with a significant contribution to pulmonary and respiratory medicine, rheumatology, neurology, oncology, and pathology and forensic medicine. Their research spans a range of clinical and pathological subjects, emphasizing tumor diagnosis and treatment.

The scientist's work frequently addresses topics related to:

  • Sarcoma Diagnosis and Treatment
  • Bone Tumor Diagnosis and Treatments
  • Vascular Tumors and Angiosarcomas
  • Neuroblastoma Research and Treatments
  • Lymphoma Diagnosis and Treatment
  • Neurofibromatosis and Schwannoma Cases
  • Cardiac tumors and thrombi

Piero Picci has contributed to multiple papers including:

  • Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups, 2020, Journal of Clinical Oncology
  • Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma, 2020, JAMA Oncology
  • Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial, 2021, Cancer
  • The sacral chordoma margin, 2020, European Journal of Surgical Oncology
  • Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab, 2021, BMC Cancer

The scientist's work has been published extensively in various venues, with highest frequency in:

  • Journal of Clinical Oncology
  • Cancers
  • Cancer
  • European Journal of Surgical Oncology
  • BMC Cancer

Frequent coauthors collaborating with Piero Picci include:

  • Emanuela Palmerini
  • Giovanni Grignani
  • Davide María Donati
  • Marco Gambarotti
  • Alessandra Longhi

The body of work reflects research concentrated on the challenges of diagnosis and treatment of soft tissue sarcomas and bone tumors, as well as addressing genetic susceptibilities in oncology patients. The collaboration network and publication history indicate active engagement with clinical trials and multidisciplinary research in tumor pathology and therapy.

Best Publications

  • Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.

    Sergio Frustaci;Franco Gherlinzoni;Antonino De Paoli;Marco Bonetti

  • Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.

    Gaetano Bacci;Alessandra Longhi;Michela Versari;Mario Mercuri

  • Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • Ewing Sarcoma: Current Management and Future Approaches Through Collaboration

    Nathalie Gaspar;Douglas S. Hawkins;Uta Dirksen;Ian J. Lewis

  • Osteosarcoma (Osteogenic sarcoma)

    Piero Picci

  • Unicameral and aneurysmal bone cysts.

    Mario Campanacci;Rodolfo Capanna;Piero Picci

  • Platelet-derived growth factors enhance proliferation of human stromal stem cells.

    Enrico Lucarelli;Amira Beccheroni;Davide Donati;Luca Sangiorgi

  • Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

    Stefano Ferrari;Sigbjorn Smeland;Mario Mercuri;Franco Bertoni

  • Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Paolo G. Casali;Jean-Yves Blay;Alexia Bertuzzi;Stefan Bielack

  • Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report

    Gaetano Bacci;Stefano Ferrari;Franco Bertoni;Pietro Ruggieri

  • Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.

    Alessandro Gronchi;Stefano Ferrari;Vittorio Quagliuolo;Javier Martin Broto

  • Chordoma of the mobile spine: fifty years of experience.

    Stefano Boriani;Stefano Bandiera;Roberto Biagini;Patrizia Bacchini

  • Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome

    Nicola Baldini;Katia Scotlandi;Giovanni Barbanti-Bròdano;Maria Cristina Manara

  • The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation

    Andrew S. Brohl;David A. Solomon;Wendy Chang;Jianjun Wang

  • Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin

    Gaetano Bacci;Piero Picci;Stefano Ferrari;Pietro Ruggieri M.D.

  • Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma.

    P Picci;L Sangiorgi;B T Rougraff;J R Neff

  • A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study

    G Grignani;Emanuela Palmerini;P. Dileo;S. D. Asaftei

  • Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival

    Stefano Ferrari;Antonio Briccoli;Mario Mercuri;Franco Bertoni

  • Synovial sarcoma: Retrospective analysis of 250 patients treated at a single institution

    Emanuela Palmerini;Eric L. Staals;Marco Alberghini;Licciana Zanella

Frequent Co-Authors

Katia Scotlandi
Katia Scotlandi Wayne State University
Mario Mercuri
Mario Mercuri University of Bologna
Franco Bertoni
Franco Bertoni Ospedale San Donato
Paolo G. Casali
Paolo G. Casali University of Milan
Angelo Paolo Dei Tos
Angelo Paolo Dei Tos University of Padua
Silvia Stacchiotti
Silvia Stacchiotti University of Milan
Alessandro Gronchi
Alessandro Gronchi University of Milan
Nicola Baldini
Nicola Baldini University of Bologna
Sakari Knuutila
Sakari Knuutila University of Helsinki
David W. P. Thomas
David W. P. Thomas University of Nottingham

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine doesn’t always mean attending medical school. There are several affordable online programs that offer alternative pathways into the healthcare field. For those drawn to health data, an online MHI (Master’s in Health Information) provides advanced skills in managing and analyzing medical information.

Medical billing and coding is a critical part of healthcare administration. If you’re curious about costs, find out how much is medical billing and coding school and explore affordable options that can help you start your career in this growing field.

Nurses looking to advance their practice can consider the cheapest FNP programs (Family Nurse Practitioner) or pursue an MSN. There are opportunities for aspiring nurses to find the cheapest online MSN programs and earn advanced credentials without the burden of high tuition.

These online options offer flexibility and accessibility, opening doors to various healthcare careers beyond the traditional path of becoming a physician.

Best Scientists Citing Piero Picci

Trending Scientists

Recently Published Articles